Henry C Pitot

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint A North Central Cancer Treatment Group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma
    H C Pitot
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 89:1699-705. 2000
  2. ncbi request reprint A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors
    Henry C Pitot
    Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Clin Cancer Res 8:712-7. 2002
  3. ncbi request reprint A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors
    Henry C Pitot
    Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer Chemother Pharmacol 58:165-72. 2006
  4. ncbi request reprint Phase II trial of irinotecan in patients with metastatic colorectal carcinoma
    H C Pitot
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 15:2910-9. 1997
  5. ncbi request reprint A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies
    Cynthia Ma
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Chemother Pharmacol 59:207-15. 2007
  6. ncbi request reprint A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors
    Grace K Dy
    Department of Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Chemother Pharmacol 55:522-30. 2005
  7. ncbi request reprint Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741
    Grace K Dy
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 25:3469-74. 2007
  8. ncbi request reprint A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer
    Alex A Adjei
    Mayo Clinic and Foundation, Departments of Oncology and Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 9:2520-6. 2003
  9. ncbi request reprint A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer
    Alex A Adjei
    Department of Oncology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Clin Cancer Res 9:115-23. 2003
  10. ncbi request reprint Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors
    Alex A Adjei
    Mayo Clinic and Foundation, Department of Oncology, Rochester, MN 55905, USA
    J Clin Oncol 20:1683-91. 2002

Detail Information

Publications32

  1. ncbi request reprint A North Central Cancer Treatment Group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma
    H C Pitot
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 89:1699-705. 2000
    ....
  2. ncbi request reprint A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors
    Henry C Pitot
    Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Clin Cancer Res 8:712-7. 2002
    ..To evaluate the toxicities, characterize the pharmacokinetics, and determine the maximum-tolerated dose of bizelesin administered once every 4 weeks...
  3. ncbi request reprint A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors
    Henry C Pitot
    Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer Chemother Pharmacol 58:165-72. 2006
    ..This phase I study evaluated the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), and pharmacokinetics (PK) of irinotecan given as a powder-filled capsule (PFC) daily for 5 days every 3 weeks...
  4. ncbi request reprint Phase II trial of irinotecan in patients with metastatic colorectal carcinoma
    H C Pitot
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 15:2910-9. 1997
    ..To evaluate the objective tumor response rate and toxicities of patients with metastatic colorectal carcinoma treated with irinotecan hydrochloride (CPT-11)...
  5. ncbi request reprint A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies
    Cynthia Ma
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Chemother Pharmacol 59:207-15. 2007
    ..Two different treatment schedules of bortezomib in combination with paclitaxel and carboplatin were tested in this phase I study to evaluate the effects of scheduling on toxicities, pharmacodynamics and clinical activity...
  6. ncbi request reprint A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors
    Grace K Dy
    Department of Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Chemother Pharmacol 55:522-30. 2005
    ..The present study was undertaken to evaluate the efficacy, toxicity, and pharmacokinetics of gemcitabine and pemetrexed when pemetrexed is administered immediately after gemcitabine...
  7. ncbi request reprint Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741
    Grace K Dy
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 25:3469-74. 2007
    ..To evaluate clinical characteristics and survival outcomes among patients with locally advanced or metastatic colorectal cancer who achieve a complete response (CR) to systemic treatment either alone or with multimodality approach...
  8. ncbi request reprint A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer
    Alex A Adjei
    Mayo Clinic and Foundation, Departments of Oncology and Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 9:2520-6. 2003
    ..This Phase I study was undertaken to define the toxicity, pharmacodynamics, and maximum tolerated dose of the combination of R115777, a farnesyl transferase inhibitor, with gemcitabine and cisplatin in patients with advanced solid tumors...
  9. ncbi request reprint A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer
    Alex A Adjei
    Department of Oncology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Clin Cancer Res 9:115-23. 2003
    ..The purpose of this study was to define the toxicity, pharmacokinetics, and clinical activity of the combination of ISIS 2503, an oligodeoxynucleotide antisense inhibitor of H-ras, and gemcitabine in patients with advanced solid tumors...
  10. ncbi request reprint Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors
    Alex A Adjei
    Mayo Clinic and Foundation, Department of Oncology, Rochester, MN 55905, USA
    J Clin Oncol 20:1683-91. 2002
    ..To compare the pharmacokinetics of continuous venous infusion (CVI) fluorouracil (5-FU) with that of oral eniluracil/5-FU and to describe toxicities and clinical activity of prolonged oral administration of eniluracil/5-FU...
  11. ncbi request reprint A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer
    Grace K Dy
    Department of Oncology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Clin Cancer Res 11:1877-83. 2005
    ..This phase I study was conducted to determine the toxicities, pharmacokinetics, and pharmacodynamics of BMS-214662, a farnesyl transferase inhibitor, in combination with paclitaxel and carboplatin, in patients with advanced solid tumors...
  12. ncbi request reprint A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer
    Grace K Dy
    Mayo Clinic, Rochester, Minnesota, 55905, USA
    Clin Cancer Res 11:3410-6. 2005
    ..To define the toxicities, pharmacodynamics, and clinical activity of the proteasome inhibitor, PS-341 (bortezomib), in patients with advanced malignancies...
  13. ncbi request reprint A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer
    Alex A Adjei
    Division of Medical Oncology, Mayo Clinic, Mayo Graduate School, Rochester, MN 55905, USA
    Invest New Drugs 20:297-304. 2002
    ..Subsequent studies revealed that PZA inhibits removal of platinum-DNA adducts in cultured A549 cells. Based on these results, we undertook a phase I study of the combination of PZA and carboplatin (CBDCA)...
  14. ncbi request reprint A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma
    Svetomir N Markovic
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Am J Clin Oncol 30:303-9. 2007
    ..We conducted a phase II trial evaluating the clinical efficacy of ABT-510 and its effects on biomarkers of angiogenesis and immunity in patients with metastatic melanoma (MM)...
  15. ncbi request reprint Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization
    Svetomir N Markovic
    Melanoma Study Group of the Mayo Clinic Cancer Center, Mayo Clinic, Rochester, MN 55905, USA
    Am J Clin Oncol 29:352-60. 2006
    ....
  16. ncbi request reprint A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer
    James A Martenson
    Mayo Clinic, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 55:1305-10. 2003
    ..Gemcitabine's radiosensitizing properties can theoretically be exploited by twice-weekly administration. This study assessed toxicity in patients with pancreatic cancer treated with radiation therapy, gemcitabine, and cisplatin...
  17. ncbi request reprint Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer
    Amanda C Ashley
    Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 110:670-7. 2007
    ..Efficacy and toxicity of oxaliplatin (Eloxatin; Sanofi-Aventis, Paris, France) combined with irinotecan (IROX) were examined in 383 patients enrolled on the IROX arm of Intergroup Study N9741...
  18. ncbi request reprint Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma
    Ravi D Rao
    Department of Medical Oncology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Cancer 106:375-82. 2006
    ..Patients with metastatic melanoma (MM) have very few therapy options. Based on reports of responses to paclitaxel and carboplatin (PC), 31 patients with MM were treated with PC...
  19. ncbi request reprint Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial
    Steven R Alberts
    Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    J Gastrointest Cancer 38:10-4. 2007
    ..Currently no effective therapies exist for patients with advanced or metastatic HCC. KW-2189, a DNA minor groove-binding agent, has shown promising activity against HCC in preclinical evaluations...
  20. pmc Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841
    George P Kim
    Mayo Clinic Jacksonville, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 27:2848-54. 2009
    ..Cross-over to the other treatment on disease progression was mandated...
  21. ncbi request reprint Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma
    Evanthia Galanis
    Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 101:2557-66. 2004
    ..In the current study, the authors investigated the safety and efficacy of in situ vaccination with Leuvectin in patients with metastatic renal cell carcinoma...
  22. ncbi request reprint Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial
    Richard M Goldberg
    Division of Hematology and Oncology, University of North Carolina at Chapel Hill, CB 7305, 3009 Old Clinic Bldg, Chapel Hill, NC 27514, USA
    J Clin Oncol 24:3347-53. 2006
    ..High rates of grade > or = 3 toxicity on IFL (resulting in some deaths) led us to reduce the starting doses of both irinotecan and FU by 20% (rIFL). This article compares rIFL with FOLFOX4...
  23. ncbi request reprint Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer
    Philip A Philip
    Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
    J Clin Oncol 23:6657-63. 2005
    ..Erlotinib (Tarceva, OSI-774; OSI Pharmaceuticals, Melville, NY) is a receptor tyrosine kinase inhibitor with specificity for the EGFR/HER1...
  24. pmc A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas
    Steven Attia
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, 600 Highland Avenue, K4 528, Madison, WI 53792, USA
    Invest New Drugs 26:369-79. 2008
    ..In conclusion, this regimen appears inactive against predominantly GR pancreatic cancer. RR M2 protein may not have a critical role in the malignant potential of pancreatic cancer...
  25. ncbi request reprint A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
    Richard M Goldberg
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, CB 7305, 3009 Old Clinic Building, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 22:23-30. 2004
    ..In this study, we compared the activity and toxicity of three different two-drug combinations in patients with metastatic colorectal cancer who had not been treated previously for advanced disease...
  26. ncbi request reprint Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide
    Cheri Enders Klein
    University of Illinois, Chicago 60612, USA
    Clin Pharmacol Ther 72:638-47. 2002
    ..The objective of the study was to develop and validate a population pharmacokinetic model for irinotecan and 2 of its metabolites, SN-38 and SN-38 glucuronide (SN-38G)...
  27. ncbi request reprint CpG analyzer, a Windows-based utility program for investigation of DNA methylation
    Yi hua Xu
    University of Wisconsin Madison, WI 53706 1599, USA
    Biotechniques 39:656, 658, 660 passim. 2005
  28. ncbi request reprint Phase II study of erlotinib in patients with advanced biliary cancer
    Philip A Philip
    Karmanos Cancer Institute, Wayne State University, 4 HWCRC, 4100 John R St, Detroit, MI 48201, USA
    J Clin Oncol 24:3069-74. 2006
    ..The primary objective of this study was to determine the proportion of patients with advanced BILI who were progression-free at 6 months...
  29. pmc Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model
    Katerina Strati
    McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, 1400 University Avenue, Madison, WI 53706, USA
    Proc Natl Acad Sci U S A 103:14152-7. 2006
    ..From this study, we identify minichromosome maintenance protein 7 (MCM7) and p16 as potentially useful biomarkers for HPV-positive head and neck cancer...
  30. ncbi request reprint Alterations in specific gene expression and focal neoplastic growth during spontaneous hepatocarcinogenesis in albumin-SV40 T antigen transgenic rats
    Yvonne P Dragan
    NCTR FDA, Jefferson, Arkansas, USA
    Mol Carcinog 40:150-9. 2004
    ....
  31. pmc Human papillomavirus 16 E5 oncogene contributes to two stages of skin carcinogenesis
    John P Maufort
    Department of Oncology and the McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53706, USA
    Cancer Res 67:6106-12. 2007
    ..Initial genetic and immunohistopathologic analyses did not determine the underlying basis for this distinct morphology, which correlates with a highly penetrant neoplastic phenotype...
  32. ncbi request reprint Mucinous appendiceal adenocarcinoma presenting 5 years after appendectomy
    Michael A Thompson
    Ann Intern Med 140:W33. 2004